A major Swedish study of 247,420 individuals with attention-deficit/hyperactivity disorder (ADHD) has found that medication ...

DELAWARE, DE, UNITED STATES, July 4, 2025 /EINPresswire.com/ -- The global Attention Deficit Hyperactivity Disorder (ADHD) market is anticipated to reach USD 18.3 billion by 2025, as a result of ...

Key symptoms of ADHD include: difficulty staying focused and paying attention, difficulty controlling behaviour, and ...

Rejection sensitivity in ADHD can make everyday feedback feel overwhelming. Here’s why it happens and how to manage it with ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

What is RSD? The condition often linked with ADHD – and how to manage it - The term rejection sensitive dysphoria isn’t a ...

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world ...

The Food and Drug Administration is revising the labeling of all extended-release stimulants used to treat attention-deficit hyperactivity disorder to include warnings about the risk of weight loss ...